| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Enliven Therapeutics, Inc.$51.09
-1.09 (-2.09%)
D 33Pipeline Score Richly Valued Biotech · Clinical
Market Cap
2.53 B
EPS
-1.66
P/E Ratio
-
Value Trade
24.85 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
20.69 M
Operating CF
-19.29 M
Total Assets
464.85 M
Total Liabilities
11.49 M
Equity
453.37 M
D/E Ratio
12,345
-1.59 %
Week
-10.55 %
1 Month
60.14 %
3 Month
96.31 %
6 Month
32.8 %
5 Year
-25.82 %
All Time
Cash Data
Cash Position
452.40 M
Monthly Burn
6.43 M
Runway
68.2 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
623.68 K
52 Week Range
14.79 - 48.53
% held by Insiders
20.99 %
% held by Institutions
71.61 %
Enterprise Value
2.08 B
Total Shares
59.33 M
Short %
18.79 %
Float Shares
45.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enliven Therapeutics, Inc.
186Total events
2Upcoming
43Tier-1 (high impact)
2020 – 2026Coverage
Upcoming catalysts 2
Event history 184
Q3 2026
◆Trial InitiationELVN-001Trial
Initiation of ENABLE-2 Phase 3 trial expected
chronic myeloid leukemiasource ↗
Q3 2026
◆End Of Phase 2 MeetingELVN-001FDA Meeting
Planned End-of-Phase 2 meeting with FDA
chronic myeloid leukemiasource ↗
Jun 15, 2026
▼Equity OfferingCorporate
Closed upsized public offering of common stock and pre-funded warrants with full exercise of underwriters' option
Jun 11, 2026
▼Equity OfferingCorporate
Pricing of upsized public offering of common stock and pre-funded warrants
Jun 11, 2026
◆Oral PresentationELVN-001Presentation
Oral presentation at EHA 2026 Congress with updated Phase 1 data for ELVN-001
chronic myeloid leukemiasource ↗
Jun 11, 2026
Jun 11, 2026
▲End Of Phase 1 MeetingELVN-001FDA Meeting
End-of-Phase 1 meeting with FDA
chronic myeloid leukemiasource ↗
Jun 4, 2026
May 27, 2026
May 12, 2026
▲AbstractELVN-001Presentation
Abstract accepted for oral presentation at EHA 2026
chronic myeloid leukemiasource ↗
May 7, 2026
●Enrollment UpdateELVN-001Trial
Enrollment continued in 80 mg once daily expansion cohort of Phase 1b trial
chronic myeloid leukemia (CML)source ↗
Drug Pipeline Intelligence
D33
Pipeline Score $170M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.1x
rNPV / MCap Top 42%
Small Cap (rank 530 of 912)
Percentile RankEnliven Therapeutics, Inc. faces pipeline headwinds (33/100), with $262M risk-adjusted pipeline value, led by ELVN-002 in HER2 Mutant Non-small Cell Lung Cancer (Phase 1), across $62B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELVN-002 Small molecule | HER2 Mutant Non-small Cell Lung Cancer | Phase 1 | NCT05650879 | 5% | $196M | ACTIVE NOT_RECRUITING | 198 | AVERAGE | D (37) | Jul 1, 2026 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ELVN-001 | chronic myeloid leukemia | Phase 1 | 2026-06-11 | 61% overall MMR; 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort; 67% overall MMR; 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Read More | Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components Read More | |
ELVN-001 | chronic myeloid leukemia | Phase 1 | 2026-06-11 | 61% overall MMR; 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort; 67% overall MMR; 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Read More | Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components Read More | |
ELVN-001 | chronic myeloid leukemia | Phase 1 | 2026-06-11 | 61% overall MMR; 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort; 67% overall MMR; 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique TKIs Read More | Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ELVN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ELVN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ELVNEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics has successfully closed an upsized public offering of 10,533,334 shares of common stock, generating approximately $460 million in gross proceeds. This offering included the full exercise of the underwriters' option to purchase additional shares. The company aims to use these funds to further its development of small molecule therapeutics.
Read more →ELVN▲ +14.3%on this newsshared move
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics has announced the pricing of an upsized public offering, selling 8,933,334 shares of common stock at $37.50 per share, along with pre-funded warrants. The offering is expected to raise around $400 million and is set to close on June 15, 2026, pending customary conditions. The company aims to address unmet medical needs through its therapeutics.
Read more →ELVN▲ +14.3%on this newsshared move
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics has announced a proposed public offering of $250 million in common stock, along with pre-funded warrants. The offering is managed by major financial institutions and is subject to market conditions. Enliven aims to address unmet medical needs through its innovative therapeutic approaches. However, the completion and terms of the offering remain uncertain.
Read more →ELVN▲ +9.1%on this news· ran to +25% by day 1shared move
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Enliven Therapeutics has announced positive updates from its Phase 1 ENABLE trial for ELVN-001, showing significant major molecular response (MMR) rates in chronic myeloid leukemia patients. The FDA has aligned with the company on the recommended dose for the upcoming Phase 3 ENABLE-2 trial, which will target patients previously treated with tyrosine kinase inhibitors. The trial demonstrated a favorable safety profile, supporting the potential of ELVN-001 as a new treatment option.
Read more →ELVNEnliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
Enliven Therapeutics will host a webcast on June 11, 2026, to discuss updated data from the Phase 1 ENABLE trial for ELVN-001 in chronic myeloid leukemia patients. The data will be presented at the EHA 2026 Congress in Stockholm. The trial evaluates ELVN-001's efficacy and safety, particularly against the T315I mutation.
Read more →ELVNEnliven Therapeutics to Present at Upcoming Investor Conferences
Enliven Therapeutics, a clinical-stage biopharmaceutical company, will participate in two upcoming investor conferences: the TD Cowen Annual Oncology Innovation Summit on May 27 and the Jefferies Global Healthcare Conference on June 4. Both events will feature fireside chats that will be webcast live. The company emphasizes its commitment to developing small molecule therapeutics aimed at improving patient outcomes.
Read more →ELVN▲ +6.8%on this news
Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated...
Enliven Therapeutics has announced that it will present additional positive data from its Phase 1 ENABLE clinical trial for ELVN-001 in patients with chronic myeloid leukemia (CML) at the EHA 2026 Congress. Notably, the updated data showcases a cumulative MMR rate of 47% with notable safety and tolerability. The presentation will detail findings from an ongoing trial which targets the BCR::ABL1 gene fusion in previously treated patients. The Congress presentation is scheduled for June 11, 2026, in Stockholm, Sweden.
Read more →ELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the
Enliven Therapeutics reported their first quarter financial results and a business update, emphasizing the strong cash position of $452 million which supports operations through early 2029. The company is preparing to initiate the Phase 3 ENABLE-2 trial for ELVN-001 in the second half of 2026, building on positive results from early Phase 1b trials. While they are optimistic about the drug's potential as a treatment for chronic myeloid leukemia, they are also facing risks related to ongoing clinical trials and operational losses.
Read more →ELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics reported its first quarter financial results for 2026, highlighting a strong cash position of $452 million that is expected to support operations until mid-2029. The company is preparing to initiate the Phase 3 ENABLE-2 trial for its lead candidate, ELVN-001, in the second half of 2026, following positive Phase 1b data. Despite a net loss of $23.6 million, the company remains optimistic about its future prospects in chronic myeloid leukemia treatment.
Read more →ELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Enliven Therapeutics reported positive initial data from its Phase 1b trial of ELVN-001 for chronic myeloid leukemia (CML). The company plans to initiate the Phase 3 ENABLE-2 pivotal trial in the second half of 2026. With a strong financial position, Enliven aims to demonstrate ELVN-001's potential as a leading treatment option for CML patients.
Read more →ELVNEnliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Enliven Therapeutics, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The event will be webcast live, allowing investors to access the discussion online. Enliven focuses on developing small molecule therapeutics aimed at improving patient outcomes.
Read more →ELVN▲ +50.3%on this news· ran to +68% by day 1
Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics has reported promising initial data from its ongoing Phase 1b ENABLE trial for ELVN-001, a treatment for chronic myeloid leukemia (CML). The data shows a 69% cumulative major molecular response (MMR) rate by 24 weeks, indicating potential effectiveness. The company is preparing for regulatory interactions with the FDA to support the initiation of a Phase 3 trial by the second half of 2026. The results reinforce ELVN-001's positioning as a potentially best-in-class treatment option.
Read more →ELVNEnliven Therapeutics Bolsters Board to Prepare for Next Phase of Development
Enliven Therapeutics has appointed Scott Garland to its Board of Directors as it prepares for a pivotal Phase 3 trial of ELVN-001 in chronic myeloid leukemia. The company aims to transition towards commercialization following positive clinical data reported in 2025. Andrew Phillips has stepped down from the Board, marking a shift in leadership as Enliven focuses on late-stage development.
Read more →ELVN▼ -10.2%on this news
Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
Enliven Therapeutics has granted an inducement stock option to its new CEO, Richard Fair, for 875,000 shares at an exercise price of $18.77. The option will vest over time, rewarding Fair for his continued service. This move is part of Enliven's strategy to enhance leadership and drive its precision oncology initiatives.
Read more →ELVN▼ -6.9%on this newsshared move
Enliven Therapeutics Announces New CEO to Drive Next Phase of Development
Enliven Therapeutics has appointed Rick Fair as its new CEO, effective December 11, 2025. Fair brings over 25 years of experience in product development, particularly in oncology and hematology. The leadership change aims to enhance the company's focus on its pivotal Phase 3 trial for ELVN-001 in chronic myeloid leukemia and advance its early pipeline assets.
Read more →ELVNEnliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Enliven Therapeutics reported its third quarter financial results, highlighting the completion of enrollment for the Phase 1b cohorts of the ENABLE trial for ELVN-001 in chronic myeloid leukemia (CML). The company is on track to initiate a pivotal Phase 3 trial in 2026, supported by a strong financial position with $478 million available. The CML community has shown positive validation for ELVN-001, which targets the BCR::ABL gene fusion.
Read more →ELVN▼ -14.6%on this news
Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting
Enliven Therapeutics announced promising data from its ENABLE Phase 1a/1b trial of ELVN-001, targeting chronic myeloid leukemia (CML) patients with atypical fusion transcripts. The drug demonstrated encouraging anti-CML activity and was well-tolerated among participants. The findings will be presented at the ASH 2025 Annual Meeting, highlighting its potential to address unmet needs in this patient population.
Read more →ELVNEnliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting
Enliven Therapeutics announced it will present data from its ENABLE Phase 1a/1b clinical trial of ELVN-001 at the SOHO 2025 Annual Meeting. The presentations will include both an oral session and a poster session, showcasing findings related to chronic myeloid leukemia. This marks an encore of previously presented data at the EHA 2025 Congress.
Read more →ELVN▲ +5.8%on this news
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 47% with 32% of
Enliven Therapeutics reported positive data for its Phase 1 trial of ELVN-001 in chronic myeloid leukemia (CML), achieving a cumulative major molecular response (MMR) rate of 47%. The company also detailed its strong financial position with $491 million in cash, expected to sustain operations into mid-2029. Despite the promising trial results, Enliven reported a net loss of $25.3 million for Q2 2025 and increasing R&D expenses. The company's plans to initiate a Phase 3 trial in 2026 highlight its commitment to advancing ELVN-001 in the competitive CML treatment landscape.
Read more →ELVN▲ +5.8%on this news
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics reported positive results from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia (CML), with a 47% cumulative major molecular response rate. The company highlighted its strong financial position with $491 million in cash, allowing for continued development. Plans for a Phase 3 trial are set for 2026, despite a reported net loss of $25.3 million in Q2 2025.
Read more →ELVN▼ -5.6%on this news
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Enliven Therapeutics has successfully closed a public offering of nearly 10 million shares of common stock, raising approximately $230 million. The offering included the full exercise of the underwriters' option to purchase additional shares. This move reflects the company's ongoing efforts to fund its development of small molecule therapeutics.
Read more →ELVNEnliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics has priced its public offering of 8,394,737 shares at $19.66 each, along with pre-funded warrants. The offering aims to raise approximately $200 million and is expected to close by June 16, 2025. The company has also granted underwriters a 30-day option to purchase additional shares.
Read more →ELVN▲ +11.4%on this newsshared move
Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress
Enliven Therapeutics announced positive data from its Phase 1 ENABLE trial of ELVN-001 for chronic myeloid leukemia (CML) at the EHA 2025 Congress. The trial reported a cumulative major molecular response (MMR) rate of 47% by 24 weeks, with a favorable safety profile across all dose levels. The company aims to initiate a pivotal Phase 3 trial in 2026, highlighting ELVN-001's potential as a new treatment option for CML patients.
Read more →ELVN▲ +11.4%on this newsshared move
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics, Inc. has announced a proposed public offering of $200 million in common stock, with an additional $30 million option for underwriters. This offering is subject to various market conditions, and there are no assurances regarding its completion or terms. Major financial institutions are participating in the offering, potentially indicating strong interest. However, the company acknowledges various risks associated with the completion of this offering, including market volatility and economic factors.
Read more →ELVNEnliven Therapeutics to Present at Upcoming Investor Conferences Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics, Inc. has announced its participation in several upcoming investor conferences, including TD Cowen's 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference. The company's management will conduct fireside chats, providing insights into their clinical-stage developments. These presentations will be webcast live, allowing for broader engagement with potential investors. The company continues to focus on the discovery and development of small molecule therapeutics.
Read more →ELVNEnliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare...
Enliven Therapeutics announced updated positive data from its Phase 1 ENABLE clinical trial of ELVN-001 in chronic myeloid leukemia (CML), revealing a cumulative major molecular response (MMR) rate of 44% by 24 weeks. Additionally, 26% of patients achieved the MMR by the same period, showing favorable comparison to existing treatments. The trial, involving 74 patients, demonstrated a good safety and tolerability profile, and updated data will be presented at the EHA Congress. Enliven is preparing for a potential pivotal trial for ELVN-001 planned for 2026.
Read more →ELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abst
Enliven Therapeutics has reported its first quarter financial results and provided a business update, highlighting significant progress in its Phase 1 ENABLE clinical trial of ELVN-001 for chronic myeloid leukemia (CML). The trial showed a cumulative major molecular response rate of 44% among patients after 24 weeks, with ELVN-001 exhibiting a favorable safety profile. The company is preparing for an oral presentation at the EHA 2025 Congress in June and plans to start a pivotal trial for ELVN-001 potentially in 2026. Despite a reported increase in net loss, Enliven's strong cash position is expected to sustain operations into late 2027.
Read more →ELVN▲ +5.2%on this news
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics, Inc. announced that it will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025, in Chicago, Illinois. The posters will cover significant topics, including a selective HER2 inhibitor and a pan-RAF inhibitor, which may enhance anti-tumor activity in various cancers. This announcement underscores Enliven's continued commitment to developing novel cancer therapeutics.
Read more →ELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting positive enrollment momentum in its clinical trials for ELVN-001 and ELVN-002. The company has a strong cash position of $313 million, which is expected to support operations until mid-2027. The FDA has granted orphan drug designation to ELVN-001 for chronic myeloid leukemia, with additional data expected in 2025.
Read more →ELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monot
Enliven Therapeutics has reported financial results for the fourth quarter and full year 2024, highlighting positive progress in clinical trials. The company has a robust cash position of $313 million, allowing for operational sustainability into mid-2027. Significant milestones are anticipated for their projects ELVN-001 and ELVN-002, with updated Phase 1 data expected in the upcoming years. Despite reporting losses, Enliven's leadership remains optimistic about trial progress and future developments.
Read more →ELVN▼ -5.7%on this news
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics, Inc. (Nasdaq: ELVN) will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025. The event will include a fireside chat with the company's management, which will be available for live streaming. Additionally, the webcast will be accessible for 90 days after the live session, allowing for broader access to information about the company's developments.
Read more →ELVN▼ -5%on this news
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24
Enliven Therapeutics reported third quarter financial results and presented positive data from the Phase 1 trial of ELVN-001, demonstrating a cumulative MMR rate of 44% in patients with chronic myeloid leukemia (CML). The company continues to develop ELVN-002 with ongoing trials evaluating its efficacy in HER2-positive tumors. With a strong cash position of approximately $292 million, the company has financial resources to support its operations into late 2026. Despite a growing net loss and rising R&D expenses, the progress in clinical development has created positive momentum for future updates.
Read more →ELVNEnliven Therapeutics to Present at the Jefferies London Healthcare Conference Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Enliven Therapeutics, Inc. announced its participation in a fireside chat at the Jefferies London Healthcare Conference scheduled for November 19, 2024. The event will provide an opportunity for management to discuss their clinical-stage developments in small molecule therapeutics. The presentation will be accessible through a live webcast, emphasizing transparency and investor engagement in the company's activities.
Read more →ELVN▲ +5.8%on this news
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Enliven Therapeutics has announced positive updates from its Phase 1 trial of ELVN-001 for chronic myeloid leukemia (CML), showing a cumulative major molecular response (MMR) rate of 44% by 24 weeks. The drug demonstrated stable responses and was well-tolerated among patients, with no dose reductions reported. The trial continues to evaluate ELVN-001's safety and efficacy in patients who have failed other treatments.
Read more →ELVN▲ +6%on this news
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
Enliven Therapeutics has announced that updated Phase 1a data for its drug ELVN-001 will be presented at the ESH-iCMLf 26th Annual John Goldman Conference. This oral presentation, scheduled for September 28, 2024, will discuss the safety and efficacy of ELVN-001, a selective inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia. The company aims to address unmet needs in cancer treatment through precision oncology.
Read more →ELVNEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, re
Enliven Therapeutics reported its financial results for Q2 2024 and announced significant progress in its clinical trials. The company dosed the first patient in the Phase 1b trial for ELVN-001, targeting patients with relapsed, refractory, or intolerant chronic myeloid leukemia (CML). Additionally, the first patient was dosed in the Phase 1a trial for ELVN-002 in patients with HER2+ metastatic breast cancer and colorectal cancer. With a robust cash position of $312 million, Enliven is well-positioned to sustain its operations and further its clinical development programs.
Read more →ELVN▲ +5.7%on this news
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
Enliven Therapeutics, a clinical-stage precision oncology company, will present at two investor conferences in June. The events include the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Annual Global Healthcare Conference on June 10. Both presentations will be available via live webcast and archived for 30 days.
Read more →ELVNEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rat
Enliven Therapeutics reported its first quarter financial results and a business update, highlighting positive proof of concept data from the Phase 1 trial of ELVN-001 in chronic myeloid leukemia (CML), with a cumulative major molecular response rate of 44%. The company secured a strong financial position, with cash and equivalents totaling $321 million, projected to extend its runway into late 2026. Additionally, advancements in the development of ELVN-002 for HER2+ cancers were announced, although the net loss increased compared to the previous year, raising concerns about escalating research and development costs.
Read more →ELVN▲ +20.2%on this news
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patie
Enliven Therapeutics has reported positive proof of concept data from a Phase 1 clinical trial of its drug ELVN-001 for chronic myeloid leukemia. The trial demonstrated an initial cumulative major molecular response (MMR) rate of 44% among response-evaluable patients by 12 weeks. ELVN-001 appeared to be well tolerated without serious adverse effects, indicating promise as a new treatment option for patients resistant or intolerant to existing therapies. The company plans to share more details during a virtual event with key opinion leaders.
Read more →ELVNEnliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Enliven Therapeutics has appointed Dr. Lori Kunkel to its Board of Directors, bringing over 25 years of experience in oncology and immunology. Dr. Kunkel has been a scientific advisor since the company's inception and will now contribute directly to its strategic direction. The company anticipates initial proof-of-concept data from its Phase 1a trial of ELVN-001 soon.
Read more →ELVN▲ +7.4%on this news
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
Enliven Therapeutics will host a virtual event on April 11, 2024, to present initial proof of concept data for ELVN-001, a selective kinase inhibitor targeting the BCR-ABL gene fusion in chronic myeloid leukemia (CML). The event will feature discussions with prominent CML experts and explore the drug's potential role in the treatment landscape.
Read more →ELVN▲ +38.8%on this news· ran to +52% by day 1
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
Enliven Therapeutics has announced a $90 million private placement financing, which includes participation from both new and existing investors. The funds will support the advancement of their clinical programs, particularly ELVN-001 and ELVN-002, extending their cash runway into late 2026. A key event is scheduled for April 11, 2024, to discuss initial proof of concept data for ELVN-001 in chronic myeloid leukemia.
Read more →ELVNEnliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
Enliven Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting progress in its clinical pipeline. The company anticipates initial proof of concept data for ELVN-001 in chronic myeloid leukemia by Q2 2024 and has received FDA clearance for ELVN-002 to evaluate its use in combination therapies for HER2+ cancers. Enliven closed the year with a robust financial position, holding $253 million in cash and equivalents.
Read more →ELVNEnliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Enliven Therapeutics, a clinical-stage precision oncology company, will participate in a panel discussion during TD Cowen's 44th Annual Health Care Conference in Boston on March 5, 2024. This event highlights Enliven's ongoing commitment to engage with investors and discuss its innovative approaches to developing small molecule kinase inhibitors. The presentation will be accessible via a live webcast, demonstrating transparency and outreach to stakeholders in the biopharmaceutical community.
Read more →ELVN▼ -8%on this news
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing t
Enliven Therapeutics announced its third-quarter financial results for 2023, highlighting significant progress in its clinical trials for ELVN-001 and ELVN-002. The company reported a strong cash position of $263 million, which secures its runway into early 2026. Despite the positive outlook, Enliven noted increased net losses and R&D expenses compared to the previous year. The company is focused on advancing both drug candidates and anticipates reporting initial proof of concept data in 2024.
Read more →ELVNEnliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, wi
Enliven Therapeutics reported financial results for Q2 2023, highlighting advancements in their Phase 1 trials for ELVN-001 and ELVN-002. The company holds a strong cash position of $278 million, enabling continued research and development efforts. Initial proof of concept data for both lead programs is anticipated in 2024. However, Enliven reported a net loss of $16.7 million this quarter, indicating rising operational costs.
Read more →ELVNFINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO FINANCIAL STATEMENTS ENLIVEN THERAPEUTICS, INC. Page Report of Independent Registered Public Accounting Firm F-2 Financials Statements as of
Enliven Therapeutics, Inc. reported its financial statements for the years ending December 31, 2022, and 2021, revealing significant losses and growing stockholders' deficits. The company posted a net loss of $37,662 for 2022, which is an increase from the previous year's loss of $24,740. Cash and cash equivalents also experienced a decline, falling from $110,024 in 2021 to $75,536 in 2022. The independent auditors expressed that the financial statements represent a fair view of the company's financial position in accordance with U.S. GAAP.
Read more →ELVNEnliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results Successfully completed merger with Imara Inc., trading under the new ticker symbol on Nasdaq, ELVN Dosed first patien
Enliven Therapeutics reported a strong start to 2023, highlighting its successful merger with Imara Inc. and entry into the Nasdaq under the ticker symbol ELVN. The company has also dosed its first patient in a Phase 1 trial for ELVN-002 targeting HER2-altered non-small cell lung cancer, while patient enrollment is progressing in the ELVN-001 trial for chronic myeloid leukemia. Financial results show the company ended the first quarter with approximately $292 million in cash, which is expected to provide a cash runway until early 2026.
Read more →ELVNto the Amended 8-K. Quantitative and Qualitative Disclosures About Market Risks Interest Rate Risk As of
Enliven Therapeutics, Inc., formerly known as Imara Inc., has completed its merger with Enliven Inc. and implemented a reverse stock split. Following the merger, the company is focused on developing small molecule inhibitors for cancer treatment. However, it has significantly incurred losses since inception and currently lacks any commercial products, expecting further operational losses in the future. The firm is currently reliant on external funding sources to support its research and development activities.
Read more →ELVNEnliven Therapeutics Closes Merger with Imara and Private Placement of $165 Million
Enliven Therapeutics has successfully completed its merger with Imara, creating a clinical-stage biopharmaceutical company focused on precision oncology. With the merger, Enliven will trade on Nasdaq under the new ticker ELVN starting February 24, 2023. The company secured $165 million in private placements, ensuring a robust cash runway into early 2026. Enliven aims to advance its pipeline of small molecule kinase inhibitors and expects to nominate a new product candidate in the first half of 2023.
Read more →ELVNIMARA INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the Plan ) of IMARA Inc., a Delaware corporation (the Company ), is to advance th
IMARA Inc. has introduced an Amended and Restated 2020 Equity Incentive Plan, intended to enhance the interests of stockholders. The plan seeks to attract, retain, and motivate key contributors by offering equity ownership opportunities and performance-based incentives. This version updates the original plan adopted in February 2020, continuing the focus on aligning the interests of participants with those of the company's stockholders.
Read more →ELVNEnliven Therapeutics, Inc. and Imara Inc. Announce Definitive Merger Agreement Transcript of Conference Call Held on
Enliven Therapeutics, Inc. and Imara Inc. Announce Definitive Merger Agreement Transcript of Conference Call Held on October 13, 2022 at 5:00 P.M. Eastern Time Good day and welcome to the Enliven Therapeutics/Imara merger announcement conference call. Please note that today s
Read more →ELVNEnliven Therapeutics and Imara Announce Merger Agreement Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven s portfolio of precision oncology programs Combined company i
Enliven Therapeutics and Imara Announce Merger Agreement Boulder, CO and Boston, MA October 13, 2022 Enliven Therapeutics, Inc. (Enliven), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, a
Read more →ELVNImara Reports Full Year 2021 Financial Results and Business Highlights Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets
Imara Reports Full Year 2021 Financial Results and Business Highlights Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary endpoint of Ar
Read more →ELVNImara Reports Third Quarter 2021 Financial Results and Business Highlights Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected i
Imara Reports Third Quarter 2021 Financial Results and Business Highlights Interim analysis data for Phase 2b clinical trials of tovinontrine (IMR-687) in patients with beta-thalassemia and sickle cell disease expected in fourth quarter of 2021 Introduction of pipeline program
Read more →ELVNImara Reports Second Quarter 2021 Financial Results and Business Highlights Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Posit
Imara Reports Second Quarter 2021 Financial Results and Business Highlights Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at the E
Read more →ELVNForward-Looking Statements and Disclaimer This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited
Advancing Novel Treatments for Hemoglobin Disorders Corporate Deck: July 2021 CONFIDENTIAL Exhibit 99.1 Forward-Looking Statements and Disclaimer This presentation may contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995
Read more →ELVNImara Announces Launch of Proposed Public Offering
Imara Announces Launch of Proposed Public Offering BOSTON, Massachusetts, July 13, 2021 Imara Inc. (the Company ) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inhe
Read more →ELVNImara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Inte
Read more →ELVNImara Reports First Quarter 2021 Financial Results and Business Highlights On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of
Imara Reports First Quarter 2021 Financial Results and Business Highlights On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the transfusion-dependent be
Read more →ELVNImara Reports Full Year 2020 Financial Results and Business Highlights Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Re
Imara Reports Full Year 2020 Financial Results and Business Highlights Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical trial dat
Read more →ELVNImara Reports Third Quarter 2020 Financial Results and Business Highlights Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designatio
Imara Reports Third Quarter 2020 Financial Results and Business Highlights Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia IMR-687 granted Orphan Drug designation from European Commission for sickle cell disease Comp
Read more →ELVNImara Reports Second Quarter 2020 Financial Results and Business Highlights Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell cl
Imara Reports Second Quarter 2020 Financial Results and Business Highlights Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and efficacy
Read more →ELVNImara Reports First Quarter 2020 Financial Results and Business Highlights Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b
Imara Reports First Quarter 2020 Financial Results and Business Highlights Strengthened Board of Directors and expanded leadership team with appointment Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia Laun
Read more →ELVNIMARA STRENGTHENS BOARD OF DIRECTORS WITH APPOINTMENT OF EDWARD R. CONNER, M.D. Industry leader with global clinical development expertise to help guide Imara's clinical advancement Imara also announces departure of Chie
IMARA STRENGTHENS BOARD OF DIRECTORS WITH APPOINTMENT OF EDWARD R. CONNER, M.D. Industry leader with global clinical development expertise to help guide Imara's clinical advancement Imara also announces departure of Chief Medical Officer, Willem Scheele BOSTON, Mass., April 23
Read more →Competitive Position
How ELVN ranks across every disease it competes inCompetitive Position is a premium feature
See how ELVN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial